These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 32501454)

  • 1. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
    Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
    Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anakinra for severe forms of COVID-19: a cohort study.
    Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
    Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
    CORIMUNO-19 Collaborative group
    Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
    Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
    JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
    Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
    Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
    Cavalli G; Larcher A; Tomelleri A; Campochiaro C; Della-Torre E; De Luca G; Farina N; Boffini N; Ruggeri A; Poli A; Scarpellini P; Rovere-Querini P; Tresoldi M; Salonia A; Montorsi F; Landoni G; Castagna A; Ciceri F; Zangrillo A; Dagna L
    Lancet Rheumatol; 2021 Apr; 3(4):e253-e261. PubMed ID: 33655218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.
    De Luca G; Cavalli G; Campochiaro C; Della-Torre E; Angelillo P; Tomelleri A; Boffini N; Tentori S; Mette F; Farina N; Rovere-Querini P; Ruggeri A; D'Aliberti T; Scarpellini P; Landoni G; De Cobelli F; Paolini JF; Zangrillo A; Tresoldi M; Trapnell BC; Ciceri F; Dagna L
    Lancet Rheumatol; 2020 Aug; 2(8):e465-e473. PubMed ID: 32835256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
    Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
    Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.